Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sodium Phenylbutyrate in MCADD
NCT06773026Phase 2Recruiting
- Start
- Jun 2025
- Primary completion
- Jan 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sodium phenylbutyrate in medium-chain acyl-CoA dehydrogenase deficiency. Primary endpoint: Number of participants with treatment related adverse events as assessed by CTCAE v5.0 at 5 weeks. Started Jun 2025; status: recruiting.
02
Drugs
sodium phenylbutyrate
03
Conditions
medium-chain acyl-CoA dehydrogenase deficiency
Beyond the preview
Go deeper on NCT06773026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06773026.